Paris: Sanofi has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Have you ever heard of the “gut-brain connection”? It refers to the relationship between our gut microbiome and cognitive ...

Eupraxia Pharmaceuticals has disclosed additional positive data from its Phase Ib/IIa RESOLVE clinical trial of EP-104GI in ...

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...

This test is particularly valuable when endoscopy doesn't reveal esophagitis yet patients continue to experience refractory ...

The following is a summary of “Gastrointestinal dysmotility is associated with proton pump inhibitor refractory esophagitis in patients with systemic sclerosis,” published in the September 2024 issue ...

Diagnosing EoE can be tricky. There’s no single test, and symptoms like trouble swallowing, chest pain, and heartburn can mimic other conditions. Often, an endoscopy with biopsies, where a tiny tissue ...

CNW/ - ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging ...